Clearmind Medicine obtains rights to psychedelic compounds to treat PTSD, mental health

Key takeaways:

• Clearmind Medicine holds the exclusive rights to psychedelic compounds developed by Yissum.
• Psychedelic compounds offer promise in treating patients with PTSD but have limited availability and viability.

Clearmind Medicine, a clinical-stage biotech company, has attained exclusive global rights to develop, produce and commercialize compounds designed to treat PTSD and other mental health conditions, according to a press release.

As part of this agreement, Clearmind is granted sole licensing rights and royalties for new treatments developed from compounds invented by researchers Rami Yaka, PhD, Ahmad Masarwa, PhD, MSc; and Avi Priel, PhD, MSc, with Yissum Research Development Co. of the Hebrew University of Jerusalem.

Current PTSD treatment options like selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors vary in their efficacy and often lead to side effects such as nausea, weight gain, sexual dysfunction and increased anxiety, among others, according to Clearmind. The company’s goal is to research and develop psychedelic-based compounds that can be released as regulated medicines, foods or supplements.

“We are excited to announce this groundbreaking patent license agreement, which reflects our strong collaboration with Yissum and the Hebrew University, a world-leading institution,” Adi Zuloff-Shani, PhD, Clearmind’s CEO, said in the release. “This agreement marks a significant stride in our mission to meet urgent mental health care needs. We believe that the psychedelic compounds covered by this agreement hold immense promise in treating complex conditions like PTSD, offering a new ray of hope to millions of people worldwide.”